Summit Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
EP
Summit Asset Management's ARKG Position: Q4 2021 in Review
Summit Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 2,788 shares — an estimated $208K sold.
Summit Asset Management first reported a position in ARKG in Q3 2020 and held it in 5 quarters. The position peaked at $329K in Q1 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.
- Summit Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
- Summit Asset Management sold 2,788 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $208K.
- Summit Asset Management first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 5 quarters.
- Summit Asset Management's ARK Genomic Revolution ETF position peaked at $329K in Q1 2021.
- 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.
Based on Summit Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.